Cinclus Pharma Holding (OM:CINPHA) - Stock Price, News & Analysis

CINPHA Stock Overview

A clinical stage pharmaceutical company, engages in the development of the drug candidate for the treatment of related diseases.

About the company

CINPHA fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Risk Analysis

Has less than 1 year of cash runway

Shares are highly illiquid

Negative shareholders equity

Revenue has declined by 68.7% over the past year

+ 1 more risk

Cinclus Pharma Holding AB (publ) Competitors

Moberg Pharma

OM:MOB

SEK 1.8b

Infant Bacterial Therapeutics

OM:IBT B

SEK 1.3b

IRLAB Therapeutics

OM:IRLAB A

SEK 806.6m

Orexo

OM:ORX

SEK 567.7m

Price History & Performance

Summary of all time highs, changes and price drops for Cinclus Pharma Holding
Historical stock prices
Current Share Price	SEK 32.80
52 Week High	SEK 40.00
52 Week Low	SEK 30.10
Beta	0
11 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	0.60%

Recent updates

Shareholder Returns

	CINPHA	SE Pharmaceuticals	SE Market
7D	-4.1%	-2.6%	-1.8%
1Y	n/a	75.3%	14.4%

Return vs Industry: Insufficient data to determine how CINPHA performed against the Swedish Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how CINPHA performed against the Swedish Market.

Price Volatility

Is CINPHA's price volatile compared to industry and market?
CINPHA volatility
CINPHA Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	11.8%
Market Average Movement	5.9%
10% most volatile stocks in SE Market	12.5%
10% least volatile stocks in SE Market	3.6%

Stable Share Price: CINPHA has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine CINPHA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2014	13	Christer Ahlberg	www.cincluspharma.com

Cinclus Pharma Holding AB (publ), a clinical stage pharmaceutical company, engages in the development of the drug candidate for the treatment of related diseases. Its lead product is linaprazan glurate for the treatment of gastroesophageal reflux disease (GERD) and peptic ulcer bacteria Helicobacter pylori (H. pylori). The company was founded in 2014 and is based in Stockholm, Sweden.

Cinclus Pharma Holding AB (publ) Fundamentals Summary

How do Cinclus Pharma Holding's earnings and revenue compare to its market cap?
CINPHA fundamental statistics
Market cap	SEK 1.53b
Earnings (TTM)	-SEK 202.83m
Revenue (TTM)	SEK 2.95m

517.1x

P/S Ratio

-7.5x

P/E Ratio

Is CINPHA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CINPHA income statement (TTM)
Revenue	SEK 2.95m
Cost of Revenue	SEK 0
Gross Profit	SEK 2.95m
Other Expenses	SEK 205.78m
Earnings	-SEK 202.83m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-4.36
Gross Margin	100.00%
Net Profit Margin	-6,870.90%
Debt/Equity Ratio	-128.7%

How did CINPHA perform over the long term?

See historical performance and comparison

Cinclus Pharma Holding OM:CINPHA Stock Report